Home >  News >  Industry >  Pharma News >  Cipla resolves funding...

Cipla resolves funding dispute with Pulmatrix over asthma drug Pumazole

Pulmazole is an inhaled iSPERSE formulation of the antifungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.

By - Ruchika Sharma
Published On 2021-11-12 08:01 GMT   |   Update On 2021-11-12 08:01 GMT
Advertisement

New Delhi: US-based biopharmaceutical company Pulmatrix Inc on Tuesday said it has sorted out a funding dispute with drug major Cipla regarding Pumazole, an underdevelopment medication for asthma.

In 2019, Cipla and Pulmatrix Inc had inked a pact to co-develop a formulation for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. Cipla Technologies LLC, a subsidiary of the company, and Pulmatrix Inc had inked a definitive agreement for the co-development and commercialisation of Pulmazole.

Advertisement
Pulmazole is an inhaled iSPERSE formulation of the antifungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma. In a statement issued on Tuesday, Pulmatrix Inc said that it has completed an amendment to the earlier agreement for the development and commercialisation of Pulmazole.
"The completion of the amendment resolves Pulmatrix's previously disclosed dispute with Cipla regarding the continued funding of the development costs for Pulmazole," it added. Pursuant to the second amendment, Cipla will continue to reimburse Pulmatrix for 50 percent of all third-party costs for the development of Pulmazole, the firm said.
Upon the timely achievement of certain development milestones, Cipla will reimburse another 10 percent of Pulmatrix's "direct costs'', it added. The development milestones for Pulmatrix's planned Phase 2 clinical trial include the dosing of 25 percent of participants in the clinical trial by June 30, 2023, and the delivery of top-line data results to the joint steering committee for the programme by June 30, 2024. "If the development milestones are not achieved within 9-months of such dates either party may terminate its obligation to fund its share of development costs," Pulmatrix Inc said.
The US firm said it has also granted Cipla exclusive rights to the development and commercialisation of Pulmazole in India, Nepal, Yemen, Iran, South Africa, Sri Lanka, Myanmar and Algeria in exchange for, under certain circumstances, 2 percent royalties on the net sales. "We are pleased to have come to this resolution, which will enable the continued development of Pulmazole globally with our valued partners at Cipla," Pulmatrix CEO Ted Raad said.
Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

After Cough Syrup Deaths, CDSCO Tightens Oversight on Drug Testing Compliance

Exemed Pharma's Empagliflozin-Vildagliptin Combo Rejected by CDSCO Panel Over Questionable Clinical Use

Ravenbhel Gets SEC Nod to Market Bilastine, Montelukast FDC, Phase IV Trial Mandated

Drugs Control Officials Caught Taking Rs 20,000 Bribe in Telangana

Contaminated Cough Syrup horror: Centre proposes license cancellation of Coldrif maker, Tamil Nadu FDA yet to act

Himachal, UP Join States Banning Coldrif Cough Syrup After MP Deaths

Toxic syrup tragedy: MP police hunt pharma co owner after child deaths

Not of Standard Quality: Gujarat orders suspension of production at two pharma cos